# Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

> **NCT00525161** · PHASE2 · TERMINATED · sponsor: **Suleiman Massarweh** · enrollment: 11 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT00525161
- **Lead sponsor:** Suleiman Massarweh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2013-01
- **Final completion:** 2015-01
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slow accrual and loss of funding
- **Last updated:** 2015-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525161, "Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00525161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*